Home/Biosyngen/Prof. Scott Burrows
PS

Prof. Scott Burrows

Scientific Advisor

Biosyngen

Roles

Scientific AdvisoratBiosyngen
Chief Financial OfficeratSpyre Therapeutics
Chief Operating Officer and Chief Financial Officer (former)atArcutis Biotherapeutics

Therapeutic Areas

Biosyngen Pipeline

DrugIndicationPhase
BRG01Nasopharyngeal carcinoma (EBV+)Phase 2
BST02Liver cancer (all types)Phase 1
BGT007Dual CAR‑T for solid tumorsInvestigator‑initiated trial
ALLO‑CELMultiple solid & liquid tumors (allogeneic)Pre‑clinical / IND filing
GGT008Colorectal, gastric, esophageal, pancreatic cancersPre‑clinical